The Percentage of n-3 Highly Unsaturated Fatty Acids in Total HUFA as a Biomarker for Omega-3 Fatty Acid Status in Tissues

A blood biomarker of omega-3 fatty acid intake and tissue status could serve as a modifiable risk factor for cardiovascular disease. The percentage of omega-3 highly unsaturated fatty acid (HUFA ≥ 20 carbons and ≥3 double bonds) in the total HUFA pool (the n-3 HUFA score) was examined as a potential blood biomarker of omega-3 fatty acids in tissues. The fatty acid composition of total lipid extracts (TLE) and phospholipid (PL) fractions were determined for plasma and erythrocytes samples of human subjects (n = 20) and the n-3 HUFA score and the sum of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) were compared. Omega-3 fatty acids in blood and tissues of rats (n = 31) and pigs (n = 48) were also determined and the associations were compared. The n-3 HUFA score is more consistent across plasma and erythrocytes, with strong correlations between TLE and PL in plasma (r = 0.93) and erythrocytes (r = 0.94). The n-3 HUFA score was less variable and blood levels correlated strongly with various animal tissues. The n-3 HUFA score is a useful blood biomarker that does not require the isolation of the PL class thereby supporting high throughput analyses. The strength of association between the n-3 HUFA score and disease risk needs to be examined.     

n-3 Polyunsaturated Fatty Acids and Atopy in Korean Preschoolers

Atopy is a growing problem for Korean children. Since eicosapentaenoic acid is a precursor of less active inflammatory eicosanoids, n-3 polyunsaturated fatty acids (PUFA) may have a protective effect on atopy. This study was undertaken to determine whether n-3 PUFA in red blood cells (RBC) is lower in atopic than in non-atopic preschoolers. Three hundred and eight Korean children aged 4–6 years were enrolled. Total RBC fatty acid composition was measured by gas chromatography. The prevalence of atopic dermatitis, allergic rhinitis, or asthma was 29%. Total RBC n-3 PUFA were lower in preschoolers with atopy than controls (9.8 ± 1.2 vs. 11.4 ± 1.6%; P < 0.05), while n-6 PUFA (33.0 ± 1.4 vs. 32.2 ± 1.0%; P < 0.05) and n-6/n-3 PUFA ratio (3.4 ± 0.6 vs. 2.8 ± 0.5; P < 0.05) were greater. The following factors were also associated with an increase in atopy: higher saturated fatty acids (39.6 ± 1.4 vs. 40.6 ± 1.9; P < 0.05) and arachidonic acid (15.3 ± 1.6 vs. 16.0 ± 2.9; P < 0.05), and lower total PUFA (43.8 ± 0.7 vs. 42.8 ± 1.4; P < 0.05) and omega-3 index (EPA + DHA; 9.1 ± 0.8 vs. 7.8 ± 0.5; P < 0.05) in RBC. Maternal history of atopy was a significant (P < 0.05) risk factor, while lactation was not. The results suggest that a reduced content of n-3 PUFA in the RBC membrane could play a role in early children atopy.     

Plasma Omega-3 Fatty Acid Response to a Fish Oil Supplement in the Healthy Elderly

Little information is available concerning whether incorporation of dietary omega-3 fatty acids into plasma lipids changes during healthy aging. Elderly (74 ± 4 years old) and young (24 ± 2 years old) adults were given a fish oil supplement for 3 weeks that provided 680 mg/day of docosahexaenoic acid and 320 mg/day of eicosapentaenoic acid, followed by a 2 week wash-out period. Compliance was monitored by spiking the capsules with carbon-13 glucose, the excretion of which was measured in breath CO₂. In response to the supplement, plasma docosahexaenoic acid rose 42% more in the elderly but eicosapentaenoic responded similarly in both groups. Despite raising docosahexaenoic acid intake by five to tenfold, the supplement did not raise plasma free docosahexaenoic acid (% or mg/dL) in either group. We conclude that healthy aging is accompanied by subtle but significant changes in DHA incorporation into plasma lipids.     

Oxidation in EPA‐ and DHA‐rich oils: an overview

Oxidation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) rich omega‐3 oils (hereafter referred to as either EPA and DHA or omega‐3) is a complicated topic, but an important one to understand. A significant number of consumers cite fishy burp and/or taste, thought to be the result of oxidation, as one of the main reasons they do not consume EPA and DHA rich oils. In addition, consumers note that some articles have raised concerns about the potential for adverse effects associated with consumption of oxidized oils. Measuring oxidation in omega‐3 oils is complicated due to the differences in chemical and physical characteristics of many commercially available products, which means not all methods to determine quality are appropriate for all types of oils. A number of consumer advocacy groups, product quality seal programs and academic groups have published data on levels of oxidation in omega‐3 oils. Overall, this data shows that commercially available omega‐3 supplements are low in oxidation. If consumers have a poor sensory experience with their omega‐3 product, they should try another product as an alternative.     

Interplay Between n-3 and n-6 Long-Chain Polyunsaturated Fatty Acids and the Endocannabinoid System in Brain Protection and Repair

The brain is enriched in arachidonic acid (ARA) and docosahexaenoic acid (DHA), long‐chain polyunsaturated fatty acids (LCPUFAs) of the n‐6 and n‐3 series, respectively. Both are essential for optimal brain development and function. Dietary enrichment with DHA and other long‐chain n‐3 PUFA, such as eicosapentaenoic acid (EPA), has shown beneficial effects on learning and memory, neuroinflammatory processes, and synaptic plasticity and neurogenesis. ARA, DHA and EPA are precursors to a diverse repertoire of bioactive lipid mediators, including endocannabinoids. The endocannabinoid system comprises cannabinoid receptors, their endogenous ligands, the endocannabinoids, and their biosynthetic and degradation enzymes. Anandamide (AEA) and 2‐arachidonoylglycerol (2‐AG) are the most widely studied endocannabinoids and are both derived from phospholipid‐bound ARA. The endocannabinoid system also has well‐established roles in neuroinflammation, synaptic plasticity and neurogenesis, suggesting an overlap in the neuroprotective effects observed with these different classes of lipids. Indeed, growing evidence suggests a complex interplay between n‐3 and n‐6 LCPUFA and the endocannabinoid system. For example, long‐term DHA and EPA supplementation reduces AEA and 2‐AG levels, with reciprocal increases in levels of the analogous endocannabinoid‐like DHA and EPA‐derived molecules. This review summarises current evidence of this interplay and discusses the therapeutic potential for brain protection and repair.     

Increased Prostaglandin Response to Oxytocin in Ewes Fed a Diet High in Omega-6 Polyunsaturated Fatty Acids

Diets high in omega-6 polyunsaturated fatty acids (n-6) are associated with increased prostaglandin F_2α (PGF_2α) synthesis in cattle, however, the specific effects on the potential prostaglandin response to an oxytocin challenge in sheep have not been reported. The aim of the current study was to determine whether oxytocin-stimulated PGF_2α was significantly increased when ewes were fed a diet high in n-6 compared with a control diet low in n-6. Merino x Border Leicester ewes (n = 30) received one of two dietary treatments, either high in n-6 (70 % oat grain) or low in n-6 (control diet, 100 % cereal/legume silage). Ewes consumed the diets for 44 days prior to two consecutive oxytocin challenges. Plasma n-6 and PGF_2α metabolite (PGFM) concentrations following oxytocin challenge were greater (P < 0.05) when ewes were fed a diet high in n-6 compared with the control diet. A higher availability of n-6 may have lead to an increased in vivo synthesis of PGF_2α, however, further research is required to determine the exact mechanisms involved.     

N-3 Polyunsaturated Fatty Acids Modulate In-Vitro T Cell Function in Type I Diabetic Patients

In this work, we assessed the in-vitro effects of eicosapentaenoic acid (EPA; C20:5n-3) and docosahexaenoic acid (DHA; C22:6n-3) (final concentration, 15 microM) on T cell blastogenesis, interleukin-2 and -4 (IL-2, IL-4) secretion, fatty acid composition and intracellular oxidative status in type I diabetic patients with or without complications. Con A stimulated lymphocyte proliferation, glucose uptake, intracellular reduced glutathione levels and catalase activity were lower in diabetics as compared to controls, regardless to the presence of complications. EPA and DHA diminished T-lymphocyte proliferation and IL-2 production but enhanced IL-4 secretion in both diabetic and control groups. No changes in the levels of reduced glutathione and in the activities of catalase and SOD were observed in control T cells cultured in the presence of EPA and DHA. However, in diabetic patients, addition of n-3 PUFA to culture induced an increase in T cell levels of reduced glutathione and hydroperoxide, and in activities of catalase and SOD. Low levels of arachidonic acid (C20:4n-6) were found in plasma membrane phospholipids of lymphocytes from diabetic patients compared to controls. Incubation of lymphocytes with EPA and DHA was associated with an incorporation of these fatty acids in membrane phospholipids. In conclusion, the beneficial effects of n-3 PUFA on T cell functions in type I diabetes could be attributed to their suppressive action and modulation of cytokine secretion, and to the improvement of intracellular oxidative status.     

Egg Yolk as Means for Providing Essential and Beneficial Fatty Acids

The new American Dietary Guidelines now recommend optimizing the types of fat consumed instead of reducing or eliminating fat from the diet. Chicken eggs are a means to deliver essential and beneficial human dietary fatty acids (FA), and can be staple component of healthy eating behavior. Additionally, polyunsaturated fatty acids can be increased in the avian egg yolk by simply incorporating selected lipid sources into the avian diet. Poultry feed rich in omega‐3 FA (omega‐3) has allowed commercialization of enriched eggs containing up to 600 mg of omega‐3. Conjugated linoleic acid (CLA) has also been used in the research setting to enrich eggs to provide a portion of the 3–4 g CLA day^?1 needed to promote weight loss to combat obesity. However, Americans consume only 50% of the omega‐3 recommended adequate intake, and average CLA consumption is under 600 mg day^?1. While a variety of foods are naturally rich in omega‐3, conventional sources of CLA are limited to bovine milk and meat, which do not provide enough CLA to produce clinical effects in a balanced diet. Since eggs and egg‐based products are common in the Western diet, eggs enriched with both omega‐3 and CLA using dietary additions to poultry feed may promote consumption of the recommended levels of these FA. This article reviews the design of poultry eggs with enhanced lipid profiles through dietary intervention, and discusses the future direction of enriched egg research.     

The Effects of Omega‐3 Polyunsaturated Fatty Acid Consumption on Mammary Carcinogenesis

The consumption of omega‐3 polyunsaturated fatty acids (n‐3 PUFA) is associated with a reduced risk of breast cancer. Studies in animals and in vitro have demonstrated mechanisms that could explain this apparent effect, but clinical and epidemiological studies have returned conflicting results on the practical benefits of dietary n‐3 PUFA for prevention of breast cancer. Effects are often only significant within a population when comparing the highest n‐3 PUFA consumption group to the lowest n‐3 group or highest n‐6 group. The beneficial effects of n‐3 PUFA eicosapentaenoic and docosahexaenoic on the risk of breast cancer are dose dependent and are negatively affected by total n‐6 consumption. The majority of the world population, including the most highly developed regions, consumes insufficient n‐3 PUFA to significantly reduce breast cancer risk. This review discusses the physiological and dietary context in which reduction of breast cancer risk may occur, some proposed mechanisms of action and meaningful recommendations for consumption of n‐3 PUFA in the diet of developed regions.     

n‐3 PUFA Esterified to Glycerol or as Ethyl Esters Reduce Non‐Fasting Plasma Triacylglycerol in Subjects with Hypertriglyceridemia: A Randomized Trial

To date, treatment of hypertriglyceridemia with long‐chain n‐3 polyunsaturated fatty acids (n‐3 PUFA) has been investigated solely in fasting and postprandial subjects. However, non‐fasting triacylglycerols are more strongly associated with risk of cardiovascular disease. The objective of this study was to investigate the effect of long‐chain n‐3 PUFA on non‐fasting triacylglycerol levels and to compare the effects of n‐3 PUFA formulated as acylglycerol (AG‐PUFA) or ethyl esters (EE‐PUFA). The study was a double‐blinded randomized placebo‐controlled interventional trial, and included 120 subjects with non‐fasting plasma triacylglycerol levels of 1.7–5.65 mmol/L (150–500 mg/dL). The participants received approximately 3 g/day of AG‐PUFA, EE‐PUFA, or placebo for a period of eight weeks. The levels of non‐fasting plasma triacylglycerols decreased 28 % in the AG‐PUFA group and 22 % in the EE‐PUFA group (P < 0.001 vs. placebo), with no significant difference between the two groups. The triacylglycerol lowering effect was evident after four weeks, and was inversely correlated with the omega‐3 index (EPA + DHA content in erythrocyte membranes). The omega‐3 index increased 63.2 % in the AG‐PUFA group and 58.5 % in the EE‐PUFA group (P < 0.001). Overall, the heart rate in the AG‐PUFA group decreased by three beats per minute (P = 0.045). High‐density lipoprotein (HDL) cholesterol increased in the AG‐PUFA group (P < 0.001). Neither total nor non‐HDL cholesterol changed in any group. Lipoprotein‐associated phospholipase A2 (LpPLA2) decreased in the EE‐PUFA group (P = 0.001). No serious adverse events were observed. Supplementation with long‐chain n‐3 PUFA lowered non‐fasting triacylglycerol levels, suggestive of a reduction in cardiovascular risk. Regardless of the different effects on heart rate, HDL, and LpPLA2 that were observed, compared to placebo, AG‐PUFA, and EE‐PUFA are equally effective in reducing non‐fasting triacylglycerol levels.     

Enrichment of Omega-3 Fatty Acids of Refined Hoki Oil

Enrichment of the omega-3 (n-3) fatty acids of refined hoki oil (RHO) intact triglycerides (TG) and via free fatty acids (FFA), was carried out in the present study using established methods of dry fractionation (DF), low temperature solvent crystallization (LTSC) and urea complexation (UC) and positional distribution of fatty acids in the intact TG was determined by Nuclear Magnetic Resonance (NMR) analysis. Results showed that n-3 fatty acids were enriched in liquid fractions of all methods except DF, where the highest concentration was obtained via the UC method (83.00 %). The FFA form of the oil produced a higher concentration (40.81 %) of n-3 fatty acids via the LTSC method compared to the TG form (31.50 %). The percentages of the total saturated fatty acid (SFA) in the liquid fractions in all methods were lower, ranging from 1.60 % (UC) to 21.44 % (DF) compared to the RHO parent oil (24.05 %). The percentages of total monounsaturated fatty acids (MUFA) in the liquid fractions were similar to the solid fractions except for the UC method where total MUFA was six times higher in the solid fraction. In LTSC-FFA and UC methods, the enrichment factor for EPA was lower, ranging from 1.61 (LTSC-FFA) to 2.83 (UC), than DHA which ranged from 1.64 (LTSC-FFA) to 3.88 (UC). EPA was preferentially located at the sn-1,3 position and DHA was significantly located at the sn-2 position which is the favoured location for intestinal digestion.     

Exploring the Effects of Omega-3 and Omega-6 Fatty Acids on Allergy Using a HEK-Blue Cell Line

Background: Allergic reactions can result in life-threatening situations resulting in high economic costs and morbidity. Therefore, more effective reagents are needed for allergy treatment. A causal relationship has been suggested to exist between the intake of omega-3/6 fatty acids, such as docosahexanoic acid (DHA), eicosapentanoic acid (EPA), docosapentanoic acid (DPA) and arachidonic acid (AA), and atopic individuals suffering from allergies. In allergic cascades, the hallmark cytokine IL-4 bind to IL-4 receptor (IL-4R) and IL-13 binds to IL-13 receptor (IL-13R), this activates the STAT6 phosphorylation pathway leading to gene activation of allergen-specific IgE antibody production by B cells. The overall aim of this study was to characterize omega-3/6 fatty acids and their effects on STAT6 signaling pathway that results in IgE production in allergic individuals. Methods: The fatty acids were tested in vitro with a HEK-Blue IL-4/IL-13 reporter cell line model, transfected with a reporter gene that produces an enzyme, secreted embryonic alkaline phosphatase (SEAP). SEAP acts as a substitute to IgE when cells are stimulated with bioactive cytokines IL-4 and/or IL-13. Results: We have successfully used DHA, EPA and DPA in our studies that demonstrated a decrease in SEAP secretion, as opposed to an increase in SEAP secretion with AA treatment. A statistical Student’s t-test revealed the significance of the results, confirming our initial hypothesis. Conclusion: We have successfully identified and characterised DHA, EPA, DPA and AA in our allergy model. While AA was a potent stimulator, DHA, EPA and DPA were potential inhibitors of IL-4R/IL-13R signalling, which regulates the STAT6 induced pathway in allergic cascades. Such findings are significant in the future design of dietary therapeutics for the treatment of allergies.     

Low n-6/n-3 PUFA Ratio Improves Lipid Metabolism,Inflammation, Oxidative Stress and Endothelial Function in Rats Using Plant Oils as n-3 Fatty Acid Source

Lipid metabolism, inflammation, oxidative stress and endothelial function play important roles in the pathogenesis of cardiovascular disease (CVD), which may be affected by an imbalance in the n‐6/n‐3 polyunsaturated fatty acid (PUFA) ratio. This study aimed to investigate the effects of the n‐6/n‐3 PUFA ratio on these cardiovascular risk factors in rats fed a high‐fat diet using plant oils as the main n‐3 PUFA source. The 1:1 and 5:1 ratio groups had significantly decreased serum levels of total cholesterol, low‐density lipoprotein cholesterol, and proinflammatory cytokines compared with the 20:1 group (p < 0.05). Additionally, the 20:1 group had significantly increased serum levels of E‐Selectin, von Willebrand factor (vWF), and numerous markers of oxidative stress compared with the other groups (p < 0.05). The 1:1 group had a significantly decreased lipid peroxide level compared with the other groups (p < 0.05). Serum levels of malondialdehyde, reactive oxygen species and vWF tended to increase with n‐6/n‐3 PUFA ratios increasing from 5:1 to 20:1. We demonstrated that low n‐6/n‐3 PUFA ratio (1:1 and 5:1) had a beneficial effect on cardiovascular risk factors by enhancing favorable lipid profiles, having anti‐inflammatory and anti‐oxidative stress effects, and improving endothelial function. A high n‐6/n‐3 PUFA ratio (20:1) had adverse effects. Our results indicated that low n‐6/n‐3 PUFA ratios exerted beneficial cardiovascular effects, suggesting that plant oils could be used as a source of n‐3 fatty acids to prevent CVD. They also suggested that we should be aware of possible adverse effects from excessive n‐3 PUFA.     

Thraustochytrids as an alternative source of omega‐3 fatty acids,carotenoids and enzymes

Currently the most common microalgae used for commercial production of omega‐3 fatty acids are marine derived, particularly from family members of Thraustochytriaceae and Crypthecodiniaceae. Thraustochytrids are marine heterotrophic fungi like microorganisms known to produce several commercially interesting biotechnological compounds including omega‐3 fatty acids such as docosahexaenoic acid (DHA), docosapentaenoic acid (DPA) and eicosapentaenoic acid (EPA), carotenoids, sterols, exopolysaccharides and enzymes. Therefore, exploring the potential of thraustochytrids has much to offer to the commercial production of bioactive compounds. In response to growing demand for omega‐3 fatty acids, various isolation, fermentation and lipid recovery strategies have been developed in recent years.     

Incorporation of Omega-3 Fatty Acids in Nile Tilapia (Oreochromis niloticus) Fed Chia (Salvia hispanica L.) Bran

This study evaluated the effect of the inclusion of chia bran in the diet of Nile tilapia on the composition of n‐3 fatty acids (FA). Omega‐3 fatty acids provide health benefits such as reducing the risks of coronary heart disease, hypertension and inflammation, and the precursor alpha‐linolenic acid is considered strictly essential because it cannot be synthesized by humans, therefore must be ingested. Tilapias grown in tanks for a period of 45 days were treated with diets supplemented with either soybean oil (TI) or chia bran (TII). Proximal composition analysis of the feeds showed no significant difference. Feed FA quantification showed that the chia diet (TII) had a higher alpha‐linolenic acid (LNA) content. A significant increase was observed in the concentrations of LNA (8.38–81.31 mg 100 g^?1 fillets), eicosapentaenoic acid (1.12–1.56 mg 100 g^?1 fillets) and docosahexaenoic acid (19.55–26.55 mg 100 g^?1 fillets) in tilapia fillets between 0 and 45 days for TII. Total lipids at 45 days under TII were fractionated into neutral lipids (67.66 %) and polar lipids (18.90 %). Thus, dietary supplementation with chia bran contributed to raising the nutritional quality of Nile tilapia fillets.     

Synthesis and Identification of AceDoxyPC,a Protectin-Containing Structured Phospholipid,Using Liquid Chromatography/Mass Spectrometry

Fatty acids have many health benefits in a great variety of diseases ranging from cardiovascular to cerebral diseases. For instance, docosahexaenoic acid (DHA), which is highly enriched in brain phospholipids, plays a major role in anti-inflammatory or neuroprotective pathways. Its effects are thought to be due, in part, to its conversion into derived mediators such as protectins. 1-Lyso,2-docosahexaenoyl-glycerophosphocholine (LysoPtdCho-DHA) is one of the physiological carrier of DHA to the brain. We previously synthesized a structured phosphatidylcholine to mimic 1-lyso,2-docosahexaenoyl-glycerophosphocholine, named AceDoPC^® (1-acetyl,2-docosahexaenoyl-glycerophosphocholine), that is considered as a stabilized form of the physiological LysoPtdCho-DHA and that is neuroprotective in experimental ischemic stroke. Considering these, the current study aimed at enzymatically oxygenate DHA contained within AceDoPC^® to synthesize a readily structured oxidized phospholipid containing protectin DX (PDX), thereafter named AceDoxyPC (1-acetyl,2-PDX-glycerophosphocholine). Identification of this product was performed using liquid chromatography/tandem mass spectrometry. Such molecule could be used as a bioactive mediator for therapy against neurodegenerative diseases and stroke.     

Short‐Chain Fatty Acids Enhance the Lipid Accumulation of 3T3‐L1 Cells by Modulating the Expression of Enzymes of Fatty Acid Metabolism

Short‐chain fatty acids (SCFA) such as acetic acid, propionic acid, and butyric acid are produced by fermentation by gut microbiota. In this paper, we investigate the effects of SCFA on 3T3‐L1 cells and the underlying molecular mechanisms. The cells were treated with acetic acid, propionic acid, or butyric acid when cells were induced to differentiate into adipocytes. MTT assay was employed to detect the viability of 3T3‐L1 cells. Oil Red O staining was used to visualize the lipid content in 3T3‐L1 cells. A triglyceride assay kit was used to detect the triacylglycerol content in 3T3‐L1 cells. qRT‐PCR and Western blot were used to evaluate the expression of metabolic enzymes. MTT results showed that safe concentrations of acetic acid, propionic acid, and butyric acid were less than 6.4, 3.2, and 0.8 mM, respectively. Oil Red O staining and triacylglycerols detection results showed that treatment with acetic acid, propionic acid, and butyric acid accelerated the 3T3‐L1 adipocyte differentiation. qRT‐PCR and Western blot results showed that the expressions of lipoprotein lipase (LPL), adipocyte fatty acid binding protein 4 (FABP4), fatty acid transporter protein 4 (FATP4), and fatty acid synthase (FAS) were significantly increased by acetic acid, propionic acid, and butyric acid treatment during adipose differentiation (p < 0.05). In conclusion, SCFA promoted lipid accumulation by modulating the expression of enzymes of fatty acid metabolism.     

Fibroblast Growth Factor-21 and the Beneficial Effects of Long-Chain n-3 Polyunsaturated Fatty Acids

Long‐chain n‐3 polyunsaturated fatty acids (LC n‐3 PUFA) in the diet protect against insulin resistance and obesity. Fibroblast growth factor‐21 (Fgf21) is a hormonal factor released mainly by the liver that has powerful anti‐diabetic effects. Here, we tested whether the beneficial metabolic effects of LC n‐3 PUFA involve the induction of Fgf21. C57BL/6 J mice were exposed to an obesogenic, corn‐oil‐based, high‐fat diet (cHF), or a diet in which corn oil was replaced with a fish‐derived LC n‐3 PUFA concentrate (cHF + F) using two experimental settings: short‐term (3 weeks) and long‐term treatment (8 weeks). CHF + F reduced body weight gain, insulinemia, and triglyceridemia compared to cHF. cHF increased plasma Fgf21 levels and hepatic Fgf21 gene expression compared with controls, but these effects were less pronounced or absent in cHF + F‐fed mice. In contrast, hepatic expression of peroxisome proliferator‐activated receptor (PPAR)‐α target genes were more strongly induced by cHF + F than cHF, especially in the short‐term treatment setting. The expression of genes encoding Fgf21, its receptors, and Fgf21 targets was unaltered by short‐term LC n‐3 PUFA treatment, with the exception of Ucp1 (uncoupling protein 1) and adiponectin genes, which were specifically up‐regulated in white fat. In the long‐term treatment setting, the expression of Fgf21 target genes and receptors was not differentially affected by LC n‐3 PUFA. Collectively, our findings indicate that increased Fgf21 levels do not appear to be a major mechanism through which LC n‐3 PUFA ameliorates high‐fat‐diet‐associated metabolic disorders.     

Incorporation of Alpha‐Linolenic Acid and Enhancement of n‐3 Fatty Acids in Nile Tilapia: a Factorial Design

A 2² factorial design (two factors at two levels, in triplicate) was performed to investigate the influence of factors A (time of treatment, 15 and 30 days) and B (chia oil content in a supplemented diet, at 2.1 and 4.2 %) in three responses of interest referring to: (a) the incorporation of alpha‐linolenic acid (LNA) in lipids of Nile tilapia fillet; (b) the enhancement of n‐3 fatty acids; and (c) the decrease in the omega‐6/omega3 (n‐6/n‐3) ratio in fish. Factors A and B were significant in the three regression models obtained and the interaction AB was a significant contributor to the LNA and n‐6/n‐3 ratio. Analysis of variance suggested three significant and predictive mathematical models. Response surfaces analyses from designs indicated higher LNA and n‐3 contents and a lower n‐6/n‐3 ratio using both factors A and B in the higher levels (30 days of treatment and 4.2 % of chia oil in the diet for fish) chosen for this study.